| ICU Bloodstream Infection Prediction: A Transformer-Based Approach for EHR Analysis O Hirszowicz, D Aran arXiv preprint arXiv:2405.00819, 2024 | | 2024 |
| Integration of transcription regulation and functional genomic data reveals lncRNA SNHG6’s role in hematopoietic differentiation and leukemia JM Hazan, R Amador, T Ali-Nasser, T Lahav, SR Shotan, M Steinberg, ... Journal of Biomedical Science 31 (1), 27, 2024 | | 2024 |
| Comparative efficacy of combined CTLA-4 and PD-1 blockade vs. PD-1 monotherapy in metastatic melanoma: a real-world study A Klein-Brill, S Amar-Farkash, K Rosenberg-Katz, R Brenner, JC Becker, ... BJC Reports 2 (1), 14, 2024 | | 2024 |
| Defective interferon signaling in the circulating monocytes of type 2 diabetic mice S Omodaka, Y Kato, Y Sato, J Falcone-Juengert, H Zhang, A Kanoke, ... bioRxiv, 2024.06. 03.597050, 2024 | | 2024 |
| SLAYER: Synthetic Lethality Analysis for Enhanced Targeted Therapy Implicates AhR inhibitor as a Target in RB1-Mutant Bladder Tumors Z Cohen, E Petrenko, AS Barisaac, ER Abu-Zhayia, C Yanovich-Ben-Uriel, ... bioRxiv, 2024.05. 01.592073, 2024 | | 2024 |
| Evaluating GPT-4 as a Clinical Decision Support Tool in Ischemic Stroke Management A Haim, M Katson, M Cohen-Shelly, S Peretz, D Aran, S Shelly medRxiv, 2024.01. 18.24301409, 2024 | | 2024 |
| 348P Long-term opioid use following treatment of localized breast cancer: A real-world analysis A Shai, E Granot-Hershkovitz, S Amar-Farkash, K Rosenberg-Katz, ... Annals of Oncology 34, S321, 2023 | | 2023 |
| Comparative Analysis of First-Line FOLFOX Treatment With and Without Anti-VEGF Therapy in Metastatic Colorectal Carcinoma: A Real-World Data Study R Brenner, S Amar-Farkash, A Klein-Brill, K Rosenberg-Katz, D Aran Cancer Control 30, 10732748231202470, 2023 | | 2023 |
| Single-cell RNA sequencing for studying human cancers D Aran Annual Review of Biomedical Data Science 6 (1), 1-22, 2023 | 4 | 2023 |
| Transformer-based time-to-event prediction for chronic kidney disease deterioration M Zisser, D Aran Journal of the American Medical Informatics Association: JAMIA: ocae025, 2023 | 1 | 2023 |
| Head-to-head effectiveness and safety of pembrolizumab plus axitinib vs. nivolumab plus ipilimumab in metastatic renal cell carcinoma in the United States. D Aran, E Granot-Hershkovitz, S Amar-Farkash, K Rosenberg-Katz Journal of Clinical Oncology 41 (16_suppl), 4532-4532, 2023 | | 2023 |
| Early assessment of sotorasib for treatment of patients with advanced non-small cell lung cancer using real-world data in the United States. D Aran, M Shahoha, K Rosenberg-Katz, S Amar-Farkash Journal of Clinical Oncology 41 (16_suppl), 1560-1560, 2023 | | 2023 |
| MAM: Flexible Monte-Carlo Agent based model for modelling COVID-19 spread H De-Leon, D Aran Journal of Biomedical Informatics 141, 104364, 2023 | 3 | 2023 |
| Exhausted intratumoral Vδ2− γδ T cells in human kidney cancer retain effector function C Rancan, M Arias-Badia, P Dogra, B Chen, D Aran, H Yang, D Luong, ... Nature Immunology 24 (4), 612-624, 2023 | 19 | 2023 |
| Implementation of machine learning models for the prediction of vaginal birth after cesarean delivery R Meyer, N Hendin, M Zamir, N Mor, G Levin, E Sivan, D Aran, A Tsur The Journal of Maternal-Fetal & Neonatal Medicine 35 (19), 3677-3683, 2022 | 20 | 2022 |
| Comparison of FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line chemotherapy for metastatic pancreatic ductal adenocarcinoma A Klein-Brill, S Amar-Farkash, G Lawrence, EA Collisson, D Aran JAMA network open 5 (6), e2216199-e2216199, 2022 | 39 | 2022 |
| Real-world data comparing FOLFIRINOX versus gemcitabine nab-paclitaxel as first-line treatment of metastatic pancreatic ductal adenocarcinoma patients in the United States. A Klein-Brill, S Amar-Farkash, G Lawrence, EA Collisson, MJ Fisch, ... Journal of Clinical Oncology 40 (16_suppl), e16271-e16271, 2022 | 1 | 2022 |
| Real-world data comparing third and subsequent line regimens for treatment of metastatic triple-negative breast cancer in the United States. D Aran, A Klein-Brill, MJ Fisch, S Amar-Farkash Journal of Clinical Oncology 40 (16_suppl), e18765-e18765, 2022 | | 2022 |
| Real-world data comparing atezolizumab plus taxane therapy versus taxane alone as first-line treatment of metastatic triple-negative breast cancer patients in the United States. D Aran, A Klein-Brill, MJ Fisch, S Amar-Farkash Journal of Clinical Oncology 40 (16_suppl), e18767-e18767, 2022 | 2 | 2022 |
| Real-world comparison of outcomes in the first line treatment of metastatic melanoma according to BRAF mutation status: Nivolumab and ipilimumab therapy vs. nivolumab monotherapy. A Klein-Brill, S Amar-Farkash, MJ Fisch, D Aran Journal of Clinical Oncology 40 (16_suppl), e21519-e21519, 2022 | | 2022 |
Atul J. ButteDirector, Bakar Computational Health Sciences Institute, University of California, San Francisco在 ucsf.edu 的电子邮件经过验证
